Search results
Results from the WOW.Com Content Network
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue ...
For premium support please call: 800-290-4726 more ways to reach us
Vivus (VVUS) shares are trading around 15% higher Tuesday after U.S. Food and Drug Administration reviewers said its weight-loss drug Qnexa indeed helps reduce weight. Shares of rivals Orexigen ...
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
VIVUS (NAS: VVUS) may have beaten its rival Arena Pharmaceuticals (NAS: ARNA) in getting an obesity drug on the market first, but its shares plunged almost 20% this morning after reporting ...
For premium support please call: 800-290-4726
For premium support please call: 800-290-4726 more ways to reach us